Senior Researcher, SHORE & Whāriki Research Centre, Massey University, New Zealand.
Research Statistician, SHORE & Whāriki Research Centre, Massey University, New Zealand.
N Z Med J. 2021 Apr 30;134(1534):66-75.
To investigate medicinal cannabis users' intentions to transition to the new prescription Medicinal Cannabis Scheme (MCS) in New Zealand.
An online survey of 3,634 past-year medicinal cannabis users completed prior to implementation of the MCS in New Zealand in April 2020. Logistic regression models were fitted to identify predictors of intended future engagement with the MCS.
Seventy-eight percent of respondents were aware of the new MCS and 66% intended to use it. Higher income (OR=1.57), younger age (OR=1.02) and smoking cannabis (v. vaping (OR=2.0) or oral ingestion in edible form (OR=2.22)) predicted intention to engage with the MCS. Conversely, Māori (OR=0.63) and those who grew their own cannabis (OR=0.52) were less likely to intend to engage with the new prescription MCS.
The lower intended engagement with the MCS by Māori, lower income groups and those who home-grow cannabis may reflect their perceptions of the MCS as restrictive and expensive.
调查新西兰新的处方医用大麻计划（MCS）实施前，医用大麻使用者转向该计划的意向。
对 2020 年 4 月新西兰 MCS 实施前的 3634 名过去一年使用医用大麻的患者进行了在线调查。使用逻辑回归模型确定与未来使用 MCS 意向相关的预测因素。
78%的受访者知晓新的 MCS，66%的人打算使用。较高的收入（OR=1.57）、较年轻的年龄（OR=1.02）和吸食大麻（与蒸气（OR=2.0）或口服可食用形式（OR=2.22）相比）预测了使用 MCS 的意向。相反，毛利人（OR=0.63）和自己种植大麻的人（OR=0.52）不太可能打算使用新的处方 MCS。
毛利人、低收入群体和自种大麻者对 MCS 的意向参与度较低，可能反映了他们对 MCS 的看法，认为该计划限制多且昂贵。
